University of Kentucky

UKnowledge
Theses and Dissertations--Public Health (M.P.H.
& Dr.P.H.)

College of Public Health

2019

Disparities in the risk of subsequent primary cancer diagnosis and
recurrence among women with breast cancer (first primary) in
Kentucky
Pierre Fwelo
University of Kentucky, fwelo.pierre@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/cph_etds
Part of the Public Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Fwelo, Pierre, "Disparities in the risk of subsequent primary cancer diagnosis and recurrence among
women with breast cancer (first primary) in Kentucky" (2019). Theses and Dissertations--Public Health
(M.P.H. & Dr.P.H.). 256.
https://uknowledge.uky.edu/cph_etds/256

This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my capstone and abstract are my original work. Proper attribution has been
given to all outside sources. I understand that I am solely responsible for obtaining any needed
copyright permissions. I have obtained needed written permission statement(s) from the
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to
UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s capstone including
all changes required by the advisory committee. The undersigned agree to abide by the
statements above.
Pierre Fwelo, Student
Dr. Steve Fleming, Committee Chair
Dr. Sarah Wackerbarth, Director of Graduate Studies

Disparities in the risk of subsequent primary cancer diagnosis and
recurrence among women with breast cancer (first primary) in
Kentucky (2004-2016)
CAPSTONE PROJECT PAPER

A paper submitted in partial fulfillment of the
requirements for the degree of
Master of Public Health
In the
University of Kentucky College of Public Health
By

Pierre Fwelo
Lexington, Kentucky
April 16, 2019

Committee Members

Steve Fleming, PhD – Chair

Robin Vanderpool, DrPH

Jaclyn McDowell, DrPH

CONTENTS
I.

ABSTRACT

3

INTRODUCTION

5

III.

LITTERATURE REVIEW

7

IV.

METHODS

II.

V.
VI.
VII.
VIII.
IX.
X.

i.

Study Design

13

ii.

Data Source

14

iii.

Demographic Covariates

14

iv.

Exposure Assessment

15

v.

Outcome Assessment

16

vi.

Statistical Analysis

16

RESULTS

16

DISCUSSION

19

ACKNOWLEDGMENTS

23

REFERENCES

24

APPENDIX: Figures and Tables

29

BIOGRAPHICAL SKETCH

40

2

I.

ABSTRACT

Background and objectives
Breast cancer is one of the most common malignancies among women in the United States.
Women residing in the state of Kentucky have breast cancer incidence and mortality rates greater
than the national average. Recent studies suggest an association between breast cancer
subtypes/hormone receptor (HR) status and the risk of recurrence and the onset of subsequent
primary cancer, however, limited research has focused on Kentucky or its Appalachian region.
Investigating these associations may potentially save lives by providing information that can be
used in breast cancer education in Kentucky, assessing the population at greater risk of
recurrence and subsequent cancer (by subtypes), increasing screening in the population at risk,
and developing tailored interventions for each region. Therefore, the purpose of this study was to
examine the relationship between breast cancer subtypes/hormone receptor status and the risk of
recurrence and/or the risk of subsequent cancers among women in Kentucky with a specific
focus on disparities in these risks that may exist between women living in Appalachia compared
to non-Appalachia.

Methods
The analysis used data from the Kentucky Cancer Registry (KCR), specifically females ages 18
or older diagnosed with primary breast cancer between 2004 and 2016. A retrospective cohort
study was conducted to assess the risk of (1) subsequent primaries and (2) recurrence among
each breast cancer subtype/HR status. Subjects’ maximum follow-up period for the cohort study
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was five years or 60 months. To assess the relationship between breast cancer subtypes and the
risk of recurrence and/or the risk of subsequent cancers, a series of Cox regression analyses were
performed. The study was conducted in two parts: first, we analyzed data from women diagnosed
between 2004 and 2016, examining HR status as a risk factor and second, we focused on women
diagnosed between 2011 and 2016, examining breast cancer subtype as a risk factor.
Results
Between 2004 and 2016, it was observed that women with estrogen receptor-positive (ER+ only)
breast cancer had a lower risk of subsequent primaries compared to women with HR+ (estrogen
receptor-positive [ER+] and progesterone receptor-positive [PR+]) breast cancer (HR:0.85, 95%
CI: 0.74,0.96). When stratified by Appalachian status, a similar trend was only seen among nonAppalachian women (HR:0.80, 95% CI: 0.69,0.94). In examining recurrence outcomes, women
with ER+, PR+, and HR-negative (HR-) breast cancer had an increased risk compared to women
with HR+ breast cancer with hazard ratios of 1.61 (1.28, 2.03), 2.09 (1.57,3.96), and 3.16 (2.64,
3.79), respectively. Clinically significant disparities in the risk of recurrence between
Appalachian and non-Appalachian women were also observed for ER+ (1.49 vs. 1.84), PR+
(2.47 vs 2.30), and HR- (2.07 vs. 2.58) breast cancer subtypes. For the focused analysis (20112016), women with Luminal A and B subtypes had a lower risk of recurrence compared to
human epidermal growth factor receptor 2 (HER2) enriched and triple negative in both the

4

overall and stratified analyses. Also, non-Appalachian women with Luminal B had a reduced
risk of subsequent cancers (HR:0.76, 95% CI: 0.59,0.99) compared to non-Appalachian women.
Conclusion
Among this population-based sample of women in Kentucky, breast cancer subtype/HR status
was associated with the risk of subsequent primaries and recurrence. There were also noted
disparities in the risk of recurrence between women who live in Appalachian Kentucky and
women living in non-Appalachia. Women living in Appalachian Kentucky tended to have lower
risk of recurrence compared to women living in non-Appalachia for similar subtypes adjusted for
several clinical, behavioral, and insurance-related variables.

II.

Introduction

Breast cancer is a disease that is characterized by the proliferation of malignant breast cells. It is
the most common malignancy in women worldwide, and the most common cause of cancerrelated death among women. It is estimated that 2.1 million new cases and 626,679 deaths will
occur worldwide in 2018 1. In the United States (U.S.), breast cancer is the most common type of
cancer and the second most common cause of death; specifically, in 2018 is estimated that there
will be 266,120 new cases of female breast cancer and 40,920 deaths will occur as a result of the
disease 2. Although the exact cause of breast cancer is unknown, multiple risk factors have been
associated with its development including tobacco use, diet, alcohol use, age at menarche, parity,
breast feeding, age at menopause, and endogenous hormones 3-6.
5

Breast cancer is often subdivided into four main molecular subtypes based on the genes
expressed by the malignant breast cells: Luminal A, Luminal B, human epidermal growth factor
receptor 2 (HER2) enriched, and basal-like (triple negative) 7,8. Luminal A subtype is
characterized by positive hormone receptors (HR) (estrogen-receptor [ER] and/or progesteronereceptor [PR]), negative HER2, and low levels of the protein Ki-67. Luminal B subtype is
characterized by positive HR (ER+ and/or PR+), and either HER2 positive or HER2 negative
with high levels of Ki-67 9. A cancerous breast cell is considered HER2-enriched or
overexpressed when it is HR negative (ER- and PR-) and HER2 positive 10. The triple negative
subtype is characterized by HR negative cancerous breast cells (ER- and PR-) and negative
HER2 11,12.

Recent studies suggest an association between breast cancer subtype/hormone receptor status and
outcomes such as recurrence and subsequent primaries13-16. Most of these studies have involved
nationwide or global analyses, which can introduce ecological fallacies 17,18. Few studies have
investigated the association in specific U.S. states or among specific geographic, medically
underserved populations such as Appalachian Kentucky. In addition, current studies have only
focused on contralateral breast cancer as a subsequent cancer rather than any other type of
subsequent cancers 13,14. Therefore, this study aimed to examine the relationship between breast
cancer subtypes and the risk of recurrence and/or the risk of any subsequent cancers in the state
of Kentucky. Furthermore, the study investigated the potential disparities in these risks between
women living in the 54-county, primarily rural Appalachian region of the state compared to
women residing in non-Appalachia (66 counties). Based on rural-urban continuum codes,
6

Kentucky is approximately 40% rural, compared to the Appalachian region, which is over 80%
rural 19-22. Rural women in the state have notable breast cancer disparities (e.g., increased
mortality, late stage diagnoses) compared to non-rural women. These disparities may be due to
geographic isolation, high prevalence of poverty, barriers to healthcare and mammography
services (e.g., transportation, educational ascertainment / literacy, social support, stigma) 20,22,23.
Exploring the impact of breast cancer subtypes on the outcomes of interest may further explain
the breast cancer inequities observed in the Appalachian region.

LITERATURE REVIEW
The following review is a synopsis of the current knowledge of the association between breast
cancer subtype/hormone receptor status and recurrence and/or subsequent primary in the
published literature. This review gathers empirical and theoretical knowledge from peerreviewed journal articles, books, governmental fact sheets, websites, and national and
international organizational reports in the field of epidemiology, medicine, oncology, public
health, and physiology. Relevant literature was found through the following databases: Google
Scholar, Web of Science, and PubMed using keywords or phrases such as breast cancer, breast
cancer recurrence, breast cancer subtypes, multiple primary, Appalachia, Kentucky and
subsequent cancer. Additional material cited in relevant works was included in the literature
review. The literature review is divided into the following sections: breast cancer, subtypes,
recurrence and subsequent primary tumors, and breast cancer in Kentucky.
7

Breast cancer
Breast cancer refers to malignant or compromised cell proliferation originating from breast tissue
3,24.

Breast cancer usually originates from the lobule, the gland the makes milk (lobular

carcinoma) or the inner lining of milk ducts, a thin tube that carries milk from the breast lobule
to the nipple (ductal carcinoma) 25-28. Breast cancer cells can metastasize through the
bloodstream, channels to nearby lymph nodes, and/or invade regional and distant organs 24,29.
Breast cancer starts the carcinogenesis process by the random and/or induced (e.g.,
electromagnetic or nuclear radiation, viruses, environmental exposure, biological hazards or
food) modification or mutation of normal cells’ DNA, RNA, tumor suppressor genes, DNA
repair genes, and/or the creation of oncogene (from proto-oncogenes) 30.

Oncogenes and tumor suppressor genes are the two principal genes that play a major role in the
carcinogenesis process. Oncogenes are mutated proto-oncogenes (i.e., normal proteins involved
in cell cycle progression) that are abnormally active and induce proliferation. Tumor suppressor
genes regulate or inhibit the proliferation of normal and mutated cells by slowing down cell
division, repairing DNA mistakes, or ordering cells to die (a process known
as apoptosis or programmed cell death) 31-33. When tumor suppressor genes and/or protooncogenes of normal cells are mutated, the neoplastic cells acquire the ability to continuously
proliferate, evade apoptosis, grow with unlimited potential, evade the immune system, and
become independent from growth factors or metastasize 34. HER2, Breast Cancer type 1
susceptibility protein (BRCA1), Breast Cancer type 2 susceptibility protein (BRCA2), and p53
are examples of oncogenes and tumor suppressor genes that play a major role in breast cancer
carcinogenesis.
8

Subtypes
Breast cancer is classified into four main molecular subtypes that are based on the protein
expressed by the neoplastic cells. The molecular subtypes include Luminal A, Luminal B, HER2
enriched, and triple negative. These breast cancer subtypes play a major role in the cancer’s
virulence, growth, metastatic ability, and responsiveness to treatment 7,9-11.
Luminal A breast cells are characterized by the presence of steroid HR (estrogen and/or
progesterone), meaning that the cancerous cells grow faster in the presence of estrogen or
progesterone. In addition, Luminal A cells have a normal amount or no HER2. Lastly, Luminal
A cells have a low expression of antigen Ki-67, a protein that indicates how fast cells are
dividing. Luminal A cells tend to grow slowly, be less aggressive, and have low recurrence rates.
They are also more responsive to endocrine treatments, thus people with Luminal A breast
cancer tend to have a high survival rate 35. Luminal B breast cancer cells are also HR+, but differ
from Luminal A breast cancer cells by the presence of an excessive amount of HER2. Neoplastic
cells can also be categorized as Luminal B when they are HR+, have a normal amount or no
HER2, and have high Ki67 level. Luminal B breast cancers have a significantly higher
proliferation rate and worse prognosis than Luminal A 36. HER2 enriched or overexpressed
breast cancer cells are HR-, meaning the neoplastic cell growth is not triggered or enhanced by
the presence of estrogen or progesterone, and have an excessive amount of HER2. They grow
and spread more aggressively than Luminal A and B subtypes. HER2 enriched breast cancer
9

cells are also more likely to be high grade and node positive than the Luminal subtypes37. Basal
like or triple negative are breast cancer cells that are both HR- and HER2 negative. They have a
high histologic grade, are very aggressive, and have the worst prognosis of all subtypes 11,12.
Numerous studies have linked breast subtype to the risk of recurrence and/or second primary
15,16.

Recurrence
Cancer recurrence refers to the reemergence of a cancer after a period of remission. It is
potentially caused by the survival of a small number of cancerous cells after treatment that may
not show up in tests during the remission period. The Surveillance, Epidemiology and End
Results (SEER) program of the National Cancer Institute (NCI) considers a new cancer of the
same site or with the same histology as an earlier one as the same primary cancer if diagnosed
within 60 months, unless the medical record specifically states that it is recurrent or metastatic
disease (https://seer.cancer.gov/tools/mphrules/mphrules_flowchart.pdf). Cancer recurrence can
be local (in or around the initial location), regional (in the lymph nodes or tissue near initial
cancer), or distant ( in organs and far from the initial location) 38. Current studies have
investigated and established an association between breast cancer subtypes and the risk of breast
cancer recurrence 15,16. Luminal A tumors are associated with the lowest risk of recurrence rates
while basal-like tumors have the highest risk; Luminal B and HER2 have intermediate risks
15,16,37,39-42.
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Subsequent Primary Tumors
A subsequent primary tumor is a new, unrelated, and histologically different primary
cancer in a person who has a previously diagnosed cancer. Among women with breast cancer as
a first primary cancer, the incidence of multiple primaries has been reported in the range of 4.1%
43

to 16.4% 44. Recent epidemiologic studies have suggested an association between breast

cancer HR status and the risk of subsequent primary tumors 13,14. One relevant study used the
National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) database
to examine the risk of a second primary (contralateral breast cancer) among 4,927 women
diagnosed with a first primary breast cancer between 1992 and 2004. The exposure and outcome
of interest were HR status and the risk of contralateral breast cancer, respectively. The study
found that women with a first primary HR+ breast tumor had an elevated risk of contralateral
primary breast cancer compared to the general population adjusted for age, race, and calendar
year (SIR = 2.22, 95% CI = 2.15, 2.29). Also, women with HR- breast tumors had a statistically
significantly higher risk of a second contralateral breast cancer diagnosis than women with HR+
breast tumors (SIR = 3.57, 95% CI = 3.38, 3.78) 14. The vast majority of literature available on
the association between HR status and subsequent primary cancers has focused on contralateral
breast cancer as the subsequent cancer 13,14. Few have looked at the risk of any other subsequent
cancers. There is a need to further investigate the potential association between breast cancer
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subtypes and the risk of either breast cancer recurrence or subsequent primary cancer. This study
will provide additional elucidation on this association by focusing on the state of Kentucky.

Breast cancer in Kentucky
The age-adjusted incidence rate of invasive female breast cancer in Kentucky during 2012-2016
is 126.3 per 100,000 (Figure 1). The incidence rate was different by Appalachia status. In
Kentucky’s Appalachian region, the incidence rate was 118.1/100,000 [95% CI: (114.5, 121.7)],
while in Kentucky’s non-Appalachian region the rate was 129.4/100,000 [(95% CI:
(127.1,131.98)] in the same period. Furthermore, the incidence of Luminal A breast cancer in
Kentucky’s Appalachian region was 73.9/100,000 [95% CI: (70.8, 77.1)], while in Kentucky’s
non-Appalachian region the rate was 86.0/100,000 [(95% CI: (83.9,88.1)] (Figure 3). Luminal B
breast cancer incidence rate in Kentucky’s Appalachian region was 11.5/100,000 [95% CI:
(10.2,12.8)], while in Kentucky’s non-Appalachian region the rate was 12.5/100,000 [(95% CI:
(11.7,13.3)] (Figure 4). HER2-enriched breast cancer incidence rate in Kentucky’s Appalachian
region was 5.6/100,000 [95% CI: (4.7,6.5)], while in Kentucky’s non-Appalachian region the
rate was 5.3/100,000 [(95% CI: (4.8,5.9)] (Figure 5). Triple negative breast cancer incidence rate
in Kentucky’s Appalachian region was 15.4/100,000 [95% CI: (14.0,17.0)], while in Kentucky’s
non-Appalachian region the rate was 14.3/100,000 [(95% CI: (13.5,15.2)] (Figure 6).
Although the overall incidence rate of female breast cancer is lower in Appalachian Kentucky as
compared to non-Appalachian Kentucky, the mortality rate is higher. The mortality rate among
non-Appalachian women was 20.7/100,000 (95% CI: (19.1,21.7) versus 23.2/100,000 (95% CI:
(21.5,25.1) among Appalachian women (Figure 2). Lower breast cancer incidence and higher
mortality rates in Appalachian KY may be explained by documented risk factors and inequities
12

in social determinants of health among Appalachian populations such as geographic isolation,
access to care barriers, (e.g., transportation, under or uninsured, educational ascertainment /
literacy, social support, stigma), poor quality of life outcomes, cultural beliefs, significant
socioeconomic barriers, later stage diagnoses, co-morbidities, and/or under-screening 20-23,45.

III.

METHODS

Study Design
This study is a retrospective cohort focused on women diagnosed with invasive breast cancer as
a first primary between 2004 and 2016 in Kentucky using KCR data. Study subjects were
followed for a maximum of 60 months from the date of the diagnosis of the first primary to the
onset of a subsequent primary cancer diagnosis and the recurrence of the first primary. The study
sample was then stratified by Appalachian status (Appalachian vs. non-Appalachian based on
county of residence; https://www.arc.gov/appalachian_region/CountiesinAppalachia.asp) to
observe its impact on the distribution of the exposure of interest (breast cancer subtypes) and the
outcomes of interest (recurrence and subsequent primary cancer). The study was limited to breast
cancer cases among women ages 18 years or older with known HR status (estrogen and/or
progesterone receptors). Breast cancer cases diagnosed at autopsy or death certificate only were
excluded from the cohort. 41,391 women were diagnosed with malignant breast cancer (first
primary) between 2004 and 2016 in Kentucky. From this sample, 31,058 satisfied the inclusion
criteria and composed the analytic cohort. 8,150 women resided in Appalachia and 22,908
resided in non-Appalachia.
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Data Source

This study used KCR data from women ages 18 years or older diagnosed with a primary
malignant breast cancer between 2004 and 2016. KCR is the official population-based cancer
registry of the Commonwealth of Kentucky, part of NCI’s SEER program, and a longstanding
member of the Centers for Disease Control and Prevention’s National Program of Cancer
Registries. KCR performs ongoing systematic collection, analysis, and interpretation of
population-based cancer data in the state of Kentucky. More information about KCR can be
obtained at https://www.kcr.uky.edu/about.php.

Demographic Covariates

The demographic characteristics of the cohort were composed of well-studied risk factors for
cancer in general, and breast cancer in particular, such as age at diagnosis, stage of the first
primary, race, tobacco use, family history (of the first primary), menopausal status, and insurance
type. Age at diagnosis was categorized as follows: <35 years, 35-44, 45-54, 55-64, 65-74, 75-84,
and 85+). Stage at diagnosis of the first primary was categorized in four groups following SEER
Summary Stage 2000 (localized, regional, distant, and unknown). Race was divided into black,
white, other and unknown. Tobacco use, family history, and menopausal status each had three
categories (Yes, No, and Unknown). Insurance status was categorized into not insured, insured
(people with private, military, and/or veteran insurance), Medicaid, Medicare, and unknown.
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Exposure Assessment

The exposure of most interest for this study was breast cancer subtypes. Because KCR lacked
data on HER2 prior to 2009, the exposure of interest for women diagnosed with breast cancer
between 2004 and 2016 was HR status (ER and PR). The study established four levels of
exposure: ER+ only, PR+ only, ER+ and PR+, and ER- and PR-.

Breast cancer cases were categorized as ER+ only when cancerous breast cells grew faster in
response to estrogen level only, PR+ only when cancerous breast cells grew faster in response to
progesterone level only, ER+ and PR+ when cancerous breast cells grew faster in response to
both estrogen and progesterone levels, and ER- and PR- when cancerous cells grew
independently of hormone level (progesterone or estrogen).

In the focused analysis, females diagnosed with breast cancer between 2011 and 2016, the
exposure of interest was the combination of HR status and HER2 status, following the typical
classification of breast cancer subtype. The subtypes were categorized independently of Ki67
levels because the KCR lacked data on this variable. The five levels of exposure for the focused
analysis were Luminal A, Luminal B, HER2 enriched, triple negative, and other. Subjects were
categorized as Luminal A when cancerous breast cells were ER+ and/or PR+, and HER-;
Luminal B when cancerous breast cells were ER+ and/or PR+, and HER2+; HER2 enriched
when cancerous breast cells were ER-, PR-, and HER2+; triple negative when cancerous breast
cells were ER-, PR-, HER2-, and Other when cancerous breast cells had borderline results,
missing one or more test(s), or not documented.
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Outcome Assessment
The outcomes of interest of the study were: (1) the onset of subsequent primary cancer and (2) a
recurrence within five years or 60 months from being diagnosed with breast cancer.

Statistical Analysis
All statistical analyses were performed using SAS version 9.4. Descriptive statistics of the
relevant variable comparing Appalachian / non-Appalachian status were conducted using a t-test
for continuous variables and chi-square for categorical variables. A series of univariate Cox
proportional-hazard regressions were performed to assess the impact of potential cofounders and
effect modifiers on the risk of subsequent cancer and recurrence. Multivariate Cox proportionalhazard regressions assessed the association between breast cancer cells HR status or subtypes
with the hazard of subsequent cancer or recurrence by region of residence.

IV.

RESULTS

ER/PR Status and Risk of Subsequent Primary Cancer and Recurrence (20042016)
The distribution of demographic characteristics was statistically different for women residing in
Appalachia compared to women in non-Appalachia for the following variables: age at diagnosis,
stage of the first primary, race, tobacco use, family history, menopausal status, number of live
births, HR status, and insurance status (Table 1). In both geographic groups, whites were the
majority (98.07% of Appalachian subjects were whites vs. 90.23% among non-Appalachian).
16

There was a higher prevalence of tobacco use among non-Appalachian residents than
Appalachian residents (36.77% vs. 33.35%). Post-menopausal subjects were more prominent in
non-Appalachia compared to Appalachia (65.03% vs. 60.97%). The prevalence of localized
breast cancer was higher among non-Appalachian subjects compared to Appalachian subjects
(64.57% vs. 60.87%). The distribution of health insurance coverage was noticeably different
between the two geographic groups. Non-Appalachian subjects had a higher prevalence of
private health insurance than Appalachian subjects (51.04% vs. 39.77%), while Appalachian
subjects had a higher prevalence of Medicaid coverage (13.07% vs. 6.69%). Non-Appalachian
residents had a higher burden of ER+ and PR+ tumors in the overall analysis (68.37% vs
66.44%) than Appalachia residents. The distribution of the outcome of interest (recurrence and
subsequent cancer) was not statistically different between Appalachians vs non-Appalachians.
After the 60 months follow-up period, 6% of the cohort were diagnosed with a recurrence of
their first primary after remission and 8% had the onset of subsequent primaries with no
statistically significant difference between the two geographic groups (Table 2). Breast cancer
was the most common type of subsequent primary cancer among Appalachian residents
(45.51%) and non-Appalachian residents (53.95%) (Table 3).
Univariate analysis results are provided in Table 4. Stage of the first primary, family history,
menopausal status, age at diagnosis, tobacco use, and insurance status had positive associations
with the risk of outcomes of interest (p<0.05). The multivariable Cox regression model results
are shown in Table 5.
Subsequent primary
In the unstratified analysis (Appalachian + non-Appalachian), subjects who were ER+ only had
a lower risk of subsequent cancer (HR:0.85, 95% CI: 0.74,0.96) than subjects who were ER+
17

and PR+. In the stratified analysis, non-Appalachian ER+ only subjects had a lower risk of
subsequent cancer (HR:0.80, 95% CI: 0.69,0.94) compared to non-Appalachian subjects who
were ER+ and PR+. Among Appalachian residents there were no statistically significant
differences among subtypes.
Recurrence
For the recurrence outcomes, disparities in the risk associated with each subtype were observed.
Compared to ER+ and PR+, Appalachian residents had the following increased hazard for ER+
only, PR+ only, and ER- and PR- (1.49, 2.47, 2.07, respectively). Non-Appalachian residents
had the following increased hazard for ER+ only, PR+ only and ER- and PR-: 1.84, 2.30, 2.58,
respectively.

ER/PR/HER2 Status and Risk of Subsequent Primary Cancer and Recurrence
(2011-2016)
Part two of the study focused on women with breast cancer diagnosed between 2011 and 2016
and observed the impact of breast subtypes (HR + HER2 status). Non-Appalachian residents had
a higher burden of Luminal A in the focused analysis (69.55% vs 66.12%) than Appalachia
residents (Table 6). Table 7 lists the results of this focused analysis.
Recurrence
Compared to Luminal A subjects, Luminal B, HER2 enriched, and triple negative women had
higher risks of recurrence with the following hazard ratios: 1.61, 2.09, 3.16, respectively (p
<0.05). After stratifying by Appalachian status, only triple negative cases had a statistically
significant increased risk among Appalachian women. For non-Appalachian women, those with
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Luminal B, HER2 enriched, and triple negatives subtypes had increased hazard of 1.69, 2.57, and
3.35, respectively (p<0.05) compared to Luminal A subtypes.
Subsequent primary
Among non-Appalachian residents, those women with Luminal B had a reduced risk of
subsequent cancers (HR:0.76, 95% CI: 0.59,0.99).

V.

DISCUSSION

The goal of the study was to examine the relationship between breast cancer HR/subtypes and
the risk of recurrence and/or the risk of subsequent cancers among women in Kentucky.
Additionally, the study investigated disparities in the mentioned-above outcomes between
women living in Appalachian Kentucky compared to women living in non-Appalachian
Kentucky. For the risk of recurrence outcome, the observed results were consistent with the
current literature 16,39-42 and showed that women with Luminal A and B subtypes had a lower risk
of recurrence compared to women with triple negative and HER2 enriched breast cancers. This is
due to the fact that Luminal A and B cancerous cells are HR+ (their growth or proliferation is
triggered by the presence of estrogen or progesterone). In order to control their growth and
proliferation, patients often receive endocrine therapy to block the HR, thus metastasis can be
controlled more effectively. The triple negative and HER2 enriched subtypes, on the other hand,
tend to spread more aggressively and are unresponsive to hormone therapy. When cancerous
breast cells spread to distant organs, they tend to re-emerge even after mastectomy or other
treatment 39. After a period of remission, cancerous cells that metastasized to distant regions and
were not killed or controlled by treatment can proliferate again 46,47. When we looked at HR
status independently of HER2 status (2004-2016 analysis), it was also observed that ER+ and
19

PR+ subjects had a lower risk of recurrence than those positive to only one HR or those negative
to both HR. Approximately 80% of breast cancers are ER+ and 65% of the ER+ tumors are also
PR+ 48. Because they are so prevalent, current endocrine treatment has been designed to target
estrogen receptors primarily and progesterone secondarily to control the growth and proliferation
of HR+ neoplastic cells. HR- (ER- and PR-) tumors grow and spread independently of the
presence of estrogen or progesterone, as is the case with triple negative tumors, thus increasing
the risk of recurrence.

ER+ only and Luminal B non-Appalachian subjects had reduced risk of subsequent cancers
compared to non-Appalachian ER+ and PR+ and Luminal B subjects (p<0.05). One potential
explanation of the reduced risk is that both respond to hormone therapy49. The majority of
subsequent tumors among these women were breast cancer. ER+ and Luminal B women often
receive endocrine therapy to treat their cancers. The treatment can have a protective effect
against subsequent primaries that are also estrogen or HR+. The association between breast
cancer subtypes and the risk of subsequent cancer needs to be further investigated.

Disparities between Appalachian and non-Appalachian women in the risk of recurrence and/or
subsequent cancer can be partially explained by the inequity in access to quality healthcare
and/or differences in cancer mortality rates between the two regions. Previous investigations
suggest that Appalachian Kentuckians experience geographic isolation, a high prevalence of
poverty, considerable barriers to healthcare (e.g., transportation, education ascertainment /
literacy, social support, stigma), and later stages at diagnosis 20-22,45. These regional disparities
are a potential reason why breast cancer incidence rates are lower and mortality rates are higher
20

among Appalachia residents compared to non-residents. Also, non-Appalachian residents with
breast cancer live longer or have a lower risk of death than Appalachian residents 20,22,23,45. By
living longer, they may live long enough to have subsequent cancers and/or recurrence. 50,51

This research adds value to the epidemiology field by identifying which subtypes/HR status
increases the risk of recurrence and subsequent cancer. In addition, the results of this
investigation may potentially save lives by providing information that can be used in breast
cancer education in Kentucky, assessing the sub-population at greater risk of recurrence and
subsequent cancer (by subtypes), increasing screening in the sub-population at risk, and
developing tailored interventions or communications messaging for each region.

This study had a number of limitations. The first limitation is that some subjects’ demographic
characteristics had “unknown” data. For example, 17.49% of the study sample had unknown
tobacco use status, 50.30% of the women had unknown number of live births, 22.15% had
unknown family history of the breast cancer, and 14.82% of subjects had unknown menopausal
status. The “unknown” data potentially introduced non-differential bias and biased results toward
the null. This can be observed in that some known risk factors such as family history or number
of children had marginal or no statistically significant impact on the risk of the outcomes.
Another potential limitation is the lack of data about occupations, socioeconomic status,
comorbidities, and alcohol use. Not adjusting for these factors could have confounded or
modified the results. The KCR dataset lacked information on Ki-67 protein, which may have
21

impacted the accuracy of the way breast cancer subtypes were defined. Lastly, the study did not
adjust for the treatment receive by each subject. As mentioned earlier, cancer treatment in
general and endocrine therapy in particular is often associated with lower risk of recurrence 46,47.
Not controlling for it could have confounded or modified the results.

In conclusion, breast cancer subtype/HR status is associated with the risk of subsequent
primaries and recurrence. Also, there are disparities in the risk of recurrence between
Appalachian and non-Appalachian women in Kentucky. Women in Appalachian KY had lower
risk of recurrence than their non-Appalachian KY counterparts for similar subtypes adjusted for
family history, menopausal status, age at diagnosis of the first primary, stage, tobacco use, and
insurance status. Biologic differences may be responsible for differences seen in
recurrence/subsequent primaries between Appalachian resident and non-Appalachian residents.
A future direction of the study is a genome sequencing analysis of collected breast cancer tissues
of Appalachian and non-Appalachian women to assess the potential biological or epigenetic
differences between the two sub-populations that may explain the observed disparities in
Kentucky
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VIII.

APPENDIX

Table 1. Descriptive statistics of the cohort of Kentucky women diagnosed with breast cancer
between 2004-2016 and satisfied the inclusion criteria.

Kentucky

Appalachia

Non-Appalachia

N= 31,058

N= 8,150

N= 22,908

p-value

Age at diagnosis
< 35

591 (1.90%)

156 (1.91%)

435 (1.90%)

35 – 44

2,956 (9.52%)

751 (9.21%)

2,205 (9.63%)

45 – 54

6,752 (21.74%)

1,690 (20.74%)

5,062 (22.10%)

55 – 64

8,489 (27.33%)

2,340 (28.71%)

6,149 (26.84%)

65 – 74

7,061 (22.73%)

1,949 (23.91%)

5,112 (22.32%)

75 – 84

4,001 (12.88%)

992 (12.17%)

3,009 (13.14%)

85 +

1,208 (3.89%)

272 (3.34%)

936 (4.09%)

Localized

19,752 (63.60%)

4,961 (60.87%)

14,791 (64.57%)

Regional

9,425 (30.35%)

6,808 (29.72%)

2,617 (29.72%)

Distant

1,731 (5.57%)

1,206 (5.26%)

525 (6.44%)

Unknown

150 (0.49%)

47 (0.58%)

103 (0.45%)

ER+ Only

3,532 (11.37%)

975 (11.96 %)

2,557 (11.16%)

PR+ Only

344 (1.11%)

99 (1.21 %)

245 (1.07%)

ER+ and

21,080 (67.87%)

5,418 (66.44%)

15,662 (68.37%)

ER- and PR-

6,102 (19.65 %)

1,658(20.34%)

4,444 (19.40%)

Black

2,126 (6.85%)

115 (1.41%)

2,011 (8.78%)

White

28,664 (92.29%)

7,993 (98.07%)

20,671 (90.23%)

Other

182 (0.59%)

11 (0.13%)

171 (0.75%)

Unknown

86 (0.28%)

31 (0.38%)

55 (0.24%)

15,107 (48.64%)

3,876 (47.56%)

11,231 (49.03%)

<0.0001

Stage

<0.0001

Subtypes

0.0152

PR+

Race

<0.0001

Tobacco user
No
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Yes

11,141 (35.87%)

2,718 (33.35%)

8,423 (36.77%)

Unknown

4,810 (15.49 %)

1,556 (19.09%)

3,254 (14.20%)

Yes

10,419 (33.55%)

2,545 (31.23%)

7,874 (34.37%)

No

14,487 (46.65%)

3,439 (42.20%)

11,048 (48.23%)

Unknown

6,152 (19.81%)

2,166 (26.57%)

3,986 (17.40%)

Pre

6,482 (20.87 %)

1,729 (21.21%)

4,753 (20.75%)

Post

19,866 (63.96%)

4,969 (60.97%)

14,897 (65.03%)

Unknown

4,710 (15.17%)

1,452 (17.82%)

3,258 (14.22%)

Not Insured

687 (2.21%)

229 (2.81%)

458 (2.00%)

Insured

14,933 (48.08%)

3,241 (39.77%)

11,692 (51.04%)

Medicaid

2,598 (8.37%)

1,065 (13.07%)

1,533 (6.69%)

Medicare

12,585 (40.52 %)

3,505 (43.01%)

9,080 (39.64%)

Unknown

255 (0.82%)

110 (0.63%)

145 (0.63%)

<0.0001

Family History

<0.0001

Menopausal Status

<0.0001

Insurance

•

Follow-up period 5 years maximum

•

Bold: Statistically significant (p < 0.05)

<0.0001
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Table 2. Outcomes after 60 months follow-up (maximum) of the analytic cohort of subjects
diagnosed with breast cancer between 2004 and 2016 in Kentucky.

Kentucky

Appalachia

Non-Appalachia

N= 31,058

N= 8,150

N= 22,908

p-value

Recurrence
No

29,045 (93.71%)

7,640 (93.74%)

21,405 (93.44%)

Yes

2,013 (6.48%)

510 (6.26%)

1,503 (6.56%)

No

28,566 (91.98%)

7,504 (92.07%)

21,062 (91.94%)

Yes

2,492 (8.02%)

646 (7.93%)

1,846 (8.06%)

0.34

Multiple primaries
0.71

Table 3. Five most frequent second primary cancers among women in the breast cancer cohort
(2004-2016).

Kentucky

Appalachia

Non-Appalachia

N= 2,492

N= 646

N= 1,846

Breast

1,290 (51.77%)

Breast

294 (45.51%)

Breast

996 (53.95%)

Lung and

291 (11.68%)

Lung and

93 (14.40%)

Lung and

198 (10.73%)

Bronchus
Melanoma and

Bronchus
77 (3.09%)

Thyroid

Bronchus
26 (4.02%)

skin
Corpus Uteri

Melanoma and

61 (3.30%)

skin
76 (3.05%)

Corpus Uteri

21 (3.25%)

Kidney and renal

57 (3.09%)

pelvis
Kidney and renal
pelvis

71 (2.81%)

Melanoma and

16 (2.48%)

Corpus Uteri

55 (2.98%)

skin
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Table 4. Risk of multiple primaries and recurrence 2004-2016 (Univariate analysis) among women in the breast cancer cohort.

Multiple Primaries
Kentucky

Appalachia

Non-Appalachia

Recurrence
Kentucky

Appalachia

Non-Appalachia

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

Ref

Ref

Ref

Ref

Ref

Ref

Subtypes
ER+ and
PR+

1.95 (1.68, 2.27)

ER+ Only

0.88 (0.77,1.00)

1.01 (0.79, 1.28)

0.83 (0.75,0.96)

1.83 (1.60, 2.08)

1.52 (1.17, 1.97)

2.61 (1.75, 3.89)

PR+ Only

0.97 (0.66, 1.43)

1.61 (0.89,2.93)

0.76 (0.46, 1.26)

2.61 (1.86, 3.65)

2.59 (1.39, 4.87)

2.85 (2.55, 3.19)

ER- and PR-

0.88 (0.79, 0.97)

0.96 (0.78, 1.17)

0.85 (0.75, 0.96)

2.70 (2.45, 2.97)

2.29 (1.88, 2.78)

Localized

Ref

Ref

Ref

Ref

Ref

Ref

Regional

1.07 (0.98, 1.16)

1.02 (0.86, 1.21)

1.08 (0.98, 1.20)

3.12 (2.85, 3.42)

2.54 (2.12, 3.03)

3.35 (3.02, 3.72)

Distant

1.43 (1.20, 1.70)

1.43 (1.04, 1.98)

1.42 (1.15,1.76)

1.91 (1.48, 2.47)

1.60 (0.99, 2.59)

2.05 (1.52, 2.77)

Unknown

1.13 (0.60, 2.10)

0.73 (0.18, 2.94)

1.30 (0.65, 2.60)

1.15 (0.43, 3.06)

1.74 (0.43, 6.98)

0.85 (0.21, 3.41)

No

Ref

Ref

Ref

Ref

Ref

Ref

Yes

1.01 (1.004, 1.20)

0.99 (0.83,1.20)

1.13 (1.02,1.25)

0.95 (0.86, 1.04)

1.09 (0.88, 1.33)

0.91 (0.81, 1.02)

Unknown

1.03 (0.93, 1.15)

0.92 (0.76,1.12)

1.08 (0.95,1.22)

0.80 (0.71, 0.91)

0.92 (0.74, 1.15)

0.75 (0.65, 0.88)

Ref

Ref

Ref

Ref

Ref

Ref

Stage

Family History

Menopausal Status
Pre

Post

1.61 (1.44, 1.79)

1.55 (1.25, 1.91)

1.63 (1.44,1.86)

0.74 (0.67, 0.82)

0.71 (0.58, 0.86)

0.75 (0.67, 0.84)

Unknown

1.26 (1.09, 1.46)

1.26 (0.96, 1.66)

1.26 (1.05, 1.50)

0.71 (0.61, 0.82)

0.69 (0.52, 0.91)

0.71 (0.60, 0.85)

< 35

Ref

Ref

Ref

Ref

Ref

Ref

35 – 44

0.94 (0.63, 1.41)

0.49 (0.23, 1.02)

1.18 (0.72, 1.95)

0.64 (0.51, 0.82)

0.67 (0.42, 1.08)

0.63 (0.48, 0.83)

45 – 54

1.31 (0.89, 1.92)

1.13 (0.59, 2.15)

1.42 (0.88, 2.28)

0.44 (0.35, 0.55)

0.50 (0.32, 0.79)

0.42 (0.32, 0.55)

55 – 64

1.63 (1.11, 2.37)

1.20 (0.64, 2.79)

1.86 (1.16, 2,98)

0.41 (0.32, 0.51)

0.45 (0.29, 0.70)

0.39 (0.30, 0.51)

65 – 74

2.26 (1.55, 3.30)

1.76 (0.94, 3.34)

2.54 (1.59, 4.06)

0.31 (0.24, 0.39)

0.34 (0.22, 0.55)

0.30 (0.23, 0.39)

75 – 84

2.44 (1.67, 3.58)

1.68 (0.88, 3.23)

2,86 (1.78, 4.59)

0.37 (0.29, 0.48)

0.38 (0.23, 0.65)

0.37 (0.27, 0.49)

85 +

2.31 (1.31, 3.38)

1.12 (0.50, 2.49)

2.89 (1.74, 4.79)

0.46 (0.33, 0.64)

0.25 (0.10, 0.61)

0.50 (0.35, 0.72)

No

Ref

Ref

Ref

Ref

Ref

Ref

Yes

1.41 (1.30, 1.54)

1.44 (1.22, 1.71)

1.41 (1.27, 1.55)

1.04 (0.94, 1.15)

1.13 (0.93, 1.38)

1.01 (0.90, 1.13)

Unknown

1.10 (0.98, 1.24)

0.91 (0.72, 1.14)

1.20 (1.04, 1.37)

1.17 (1.04, 1.15)

1.07 (0.85, 1.36)

1.22 (1.06, 1.42)

Insured

Ref

Ref

Ref

Ref

Ref

Ref

Not Insured

1.21 (0.91, 1.60)

1.21 (0.73, 1.98)

1.22 (0.87, 1.72)

1.29 (0.98, 1.68)

1.35 (0.87, 2.12)

1.40 (0.98, 1.99)

Medicaid

1.43 (1.23, 1.66)

1.46 (1.13, 1.88)

1.44 (1.20, 1.74)

1.56 (1.34, 1.80)

1.66 (1.31, 2.11)

1.54 (1.28, 1.84)

Medicare

1.73 (1.59, 1.88)

1.81 (1.52, 2.16)

1.71 (1.57, 1.89)

0.91 (0.83,1.01)

0.92 (0.75, 1.13)

0.91 (0.82, 1.02)

Unknown

1.77 (1.17, 2.66)

2.01 (1.12, 3.61)

1.61 (0.89, 2.93)

1.06 (0.61 ,1.84)

1.14 (0.54, 2.42)

1.03 (0.46, 2.29)

Age at diagnosis

Tobacco user

Insurance

•

Bold: Statistically significant (p < 0.05)

•

HR: Hazard ratio
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Table 5. Multivariable logistic regression analysis for predicting association between breast cancer subtypes and the outcomes 20042016. Adjusted for family history, menopausal status, age at diagnosis, stage, tobacco use, and insurance status.

Multiple Primaries
Kentucky

Appalachia

Non-Appalachia

Recurrence
Kentucky

Appalachia

Non-Appalachia

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

Ref

Ref

Ref

Ref

Ref

Ref

ER+ Only

0.85 (0.74, 0.96)

0.98 (0.77,1.25)

0.80 (0.69, 0.94)

1.75 (1.53, 1.99)

1.49 (1.15, 1.95)

1.84 (1.58, 2.14)

PR+ Only

1.05 (0.71, 1.54)

1.71 (0.94, 3.12)

0.82 (0.49, 1.36)

2.38 (1.69, 3.33)

2.47 (1.31, 4.66)

2.30 (1.54, 3.43)

ER- and PR-

0.94 (0.84, 1.04)

1.03 (0.84, 1.26)

0.91 (0.80, 1.03)

2.44 (2.21, 2.69)

2.07 (1.99, 3.13)

2.58 (2.31, 2.89)

Subtypes
ER+ and
PR+

•

Bold: Statistically significant
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Table 6. Distribution of the exposure of interest among women in the breast cancer cohort (2011-2016).

Kentucky

Appalachia

Non-Appalachia

p-

N= 15,371

N= 3,997

N= 11,374

value

Subtypes
Luminal A

10,554 (68.66%)

2,643 (66.12%)

7,911 (69.55%)

Luminal B

1,574 (10.24 %)

429 (10.73%)

1,145 (10.07%)

HER2 enriched

719 (4.68%)

207 (5.18%)

512 (4.50%)

Triple Negative

1,826 (11.88%)

512 (12.81%)

1,314 (11.55%)

Other

698 (4.54%)

206 (5.15%)

492 (4.33%)

•

Luminal A: ER+ and/or PR +, HER2-

•

Luminal B: ER+ and/or PR +, HER2+

•

HER2 enriched: ER-, PR-, HER2+

•

Triple negative: ER-, PR-, HER2-

•

Other: Borderline result, one or more test(s) not performed, not documented

0.0014
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Table 7. Multivariable logistic regression analysis for predicting association between breast cancer subtypes and the outcomes 20112016. Adjusted for family history, menopausal status, age at diagnosis, stage, tobacco use, and insurance status.

Multiple Primaries
Kentucky

Appalachia

(Overall)

Recurrence
Non-

Kentucky

Appalachia

(Overall)

Appalachia

Non-Appalachia

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

Luminal A

Ref

Ref

Ref

Ref

Ref

Ref

Luminal B

0.82 (0.66, 1.02)

0.97 (0.65, 1.43)

0.76 (0.59,0.99)

1.61 (1.28,2.03)

1.42 (0.89, 2.29)

1.69 (1.29, 2.20)

HER2 enriched

0.87 (0.64, 1.18)

1.09 (0.65, 1.86)

0.77 (0.45, 1.31)

2.09 (1.57, 2.80)

1.03 (0.49, 2.15)

2.57 (1.87, 3.53)

Triple Negative

0.85 (0.70,1.04)

0.94 (0.68, 1.40)

0.81 (0.64, 1.03)

3.16 (2.64, 3.79)

2.76 (1.91, 3.98)

3.35 (2.72, 4.13)

Other

1.29 (1.01,1.65)

1.13 (0.69, 1.84)

1.37 (1.02, 1.83)

0.99 (0.63, 1.530

1.21 (0.58, 2.51)

0.88 (0.50, 1,54)

Subtypes

•

Bold: Statistically significant

•

Luminal A: ER+ and/or PR +, HER2-

•

Luminal B: ER+ and/or PR +, HER2+

•

HER2 enriched: ER-, PR-, HER2+

•

Triple negative: ER-, PR-, HER2-

•

Other: Borderline result, one or more test(s) not performed, not documented
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